newsfilter
← Latest News
Earnings Call Transcripts·

Jeffries Global Healthcare Conference in London - SUTRO BIOPHARMA INC

  • Explicit Guidance:

    • STRO-4 (Tissue Factor ADC): Initiation of dose expansion in earlier-line patient populations in the first half of 2027; expectation of a more complete efficacy dataset during this period.
    • STRO-6 (Integrin Beta-6 ADC): Initial data delivery expected in the second half of 2027.
    • PTK7 (Dual Payload ADC): IND filing on track for the end of 2026 with entry into the clinic in early 2027.
    • Pipeline Expansion: Commitment to advance three programs into the clinic by end of 2027 (accelerated from a prior 2029 timeline; currently at two programs in clinic, one pending IND).
    • Dosing/Target Parameters: STRO-4 dosing at 3–4 mg/kg (50–100% higher than approved competitor Tivdak); STRO-6 starting at 1.5 mg/kg; PTK7 dual payload dosing demonstrated up to 25 mg/kg.
  • Business-Segment Outlook:

    • Platform Validation: Aiming to validate the platform via two single-payload ADCs (STRO-4, STRO-6) with low neutropenia/cytopenia rates, serving as a precursor to safe dual and triple payload combinations to overcome resistance.
    • Payload Portfolio: Expanding proprietary payload library to include tubulins, DDRIs, IOs, and an undisclosed new cytotoxic class; planning to fine-tune payload ratios (e.g., 1+2, 1+3, 8+2) and achieve DAR-8, DAR-10, and DAR-16 configurations.
    • Technology Differentiation: Leveraging cell-free technology to utilize beta-glucuronidase linkers (cleaved in tumor lysosomes) and non-natural amino acids for site-specific conjugation, targeting a "best-in-class" safety profile compared to conventional val-cit linkers.
    • Partnerships: Ongoing collaboration with Astellas on two dual payload programs combining STING agonists with Exatecan, increasing clinical asset count to nearly three dual-payload programs.
  • Market and Competitive Outlook:

    • Resistance Solutions: Positioning dual payloads specifically to address resistance mechanisms observed with topoisomerase (ToPo) and microtubule inhibitor (MTI) payloads in the clinic.
    • Competitive Landscape: Claiming acceleration ahead of competitors (referencing "China" and US peers); anticipating competitive programs with 2.5 years of clinic time but limited data disclosure, whereas Sutro is accelerating to clinical readouts within 7 months of pivot.
    • Indication Strategy: Focusing on heavily pretreated populations (3rd to 7th line) in pancreatic, head and neck, and lung cancers to demonstrate activity where competitors fail; planning to trim STRO-6 basket to head and neck and lung cancer once active doses are defined to maximize signal clarity.
    • Drug Characteristics: STRO-4 demonstrating efficacy in Irinotecan-exposed patients (previously thought to reduce sensitivity to ToPo payloads); STRO-6 utilizing Exatecan (more potent than Belotecan or Deruxtecan) for lung cancer segments including squamous, non-squamous, and small cell.
  • Macro / Industry Outlook:

    • Industry Trend: Anticipated shift in the ADC landscape from first-generation MTI/ToPo payloads to dual payload formats to overcome resistance and expand therapeutic windows.
    • Standard of Care: Acknowledgment that combination chemotherapy (ToPo + MMAE) is the standard of care, influencing the selection of payload combinations for dual ADCs.
  • Strategic Initiatives:

    • Pivot Execution: Successfully transformed business model from "discovery platform" to "clinical development company" in 18 months, moving from 0 to 2 clinical programs and 1 pending IND.
    • Dose Optimization: Moving to higher dose levels (3–4 mg/kg for STRO-4, 1.5 mg/kg for STRO-6) compared to initial expectations to maximize potency and therapeutic index.
    • Clinical Trial Design: Implementing "backfill cohorts" of 10–12 patients per optimized dose/indication to enrich data and generate robust efficacy signals in early-line settings; planning to open regulatory conversations for pivotal trial design upon next data release.
    • Mitigation Strategies: Testing and implementing mitigation strategies for ocular toxicity and stomatitis to further improve tolerability, referencing data from ELOHAIR and Tivdak.
  • Risks and Headwinds to Outlook:

    • Data Interpretation Risks: Early efficacy signals derived from heavily pretreated, small-N cohorts (e.g., 1 out of 3 patients) may require larger confirmation to be deemed meaningful in the marketplace.
    • Regulatory/Investigator Delays: Enrolling Irinotecan-naive patients for STRO-4 is anticipated to be slower due to investigator hesitation without mature safety/efficacy data.
    • Toxicity Management: Potential for overlapping myelosuppression with dual payloads (ToPo + MMAE) and the complexity of managing target-related toxicities (ocular, stomatitis) without mitigation.
    • Trial Complexity: The need to balance DAR levels and payload ratios (e.g., 8+2 vs 4+4) to avoid target toxicity from one payload before the other reaches effective exposure.
  • Management Tone on the Future:

    • High Confidence: Expressed strong conviction in the platform's ability to deliver activity in heavily pretreated patients and replicate PK profiles across assets (STRO-4 to STRO-6).
    • Speed and Aggression: Emphasized a timeline "faster than China" for clinical development and a "bold ambition" to validate the platform and launch dual payloads quickly.
    • Differentiation: Rejected a "Me Too" strategy, asserting exclusive in-house innovation and unique positioning to deliver dual payloads with superior safety windows compared to conventional tech.
    • Caveats: Explicitly cautioned against comparing data to earlier-line patient populations ("apples to apples" comparison required due to 30–50% performance reduction in later lines).
  • Miscellaneous:

    • Preclinical Validation: Dual payload models (PDX) demonstrated superior re-challenge efficacy in MTI-resistant and Topo-ADC-resistant models (ovarian and breast cancer).
    • PK Stability: STRO-4 maintains a 98% DAR-8 configuration with a 7-day half-life and no free payload spike in circulation.
    • Collaboration Scope: Astellas collaboration focuses on dual modalities (STING agonist + Exatecan), contrasting with Sutro's dual payload focus.
Company
SUTRO BIOPHARMA INC
Keywords
SUTRO BIOPHARMA INC